143 related articles for article (PubMed ID: 35961639)
21. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
22. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
23. FDG PET/CT in a Patient With Mantle Cell Lymphoma and COVID-19: Typical Findings.
Playe M; Siavellis J; Braun T; Soussan M
Clin Nucl Med; 2020 Jul; 45(7):e305-e306. PubMed ID: 32453077
[TBL] [Abstract][Full Text] [Related]
24. Extranodal NK/T-Cell Lymphoma With Widespread Cutaneous and Subcutaneous Involvement on 18 F-FDG PET/CT.
Filizoglu N; Ozguven S; Ones T; Turoglu HT; Erdil TY
Clin Nucl Med; 2022 Oct; 47(10):e630-e631. PubMed ID: 35383610
[TBL] [Abstract][Full Text] [Related]
25. Staging in childhood lymphoma: differences between FDG-PET and CT.
Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
[TBL] [Abstract][Full Text] [Related]
26. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Gill S; Wolf M; Prince HM; Januszewicz H; Ritchie D; Hicks RJ; Seymour JF
Clin Lymphoma Myeloma; 2008 Jun; 8(3):159-65. PubMed ID: 18650179
[TBL] [Abstract][Full Text] [Related]
27. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
28. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
Paes FM; Kalkanis DG; Sideras PA; Serafini AN
Radiographics; 2010 Jan; 30(1):269-91. PubMed ID: 20083598
[TBL] [Abstract][Full Text] [Related]
29. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
[TBL] [Abstract][Full Text] [Related]
33. [Pretreatment evaluation of
Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
[No Abstract] [Full Text] [Related]
34. Extranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essay.
Kashyap R; Rai Mittal B; Manohar K; Balasubramanian Harisankar CN; Bhattacharya A; Singh B; Malhotra P; Varma S
Cancer Imaging; 2011 Nov; 11(1):166-74. PubMed ID: 22123338
[TBL] [Abstract][Full Text] [Related]
35. [Value of Pretherapeutic
Ding CY; Liu HY; Guo Z; Li TN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):438-443. PubMed ID: 28446289
[TBL] [Abstract][Full Text] [Related]
36. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
37. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Bailly C; Carlier T; Berriolo-Riedinger A; Casasnovas O; Gyan E; Meignan M; Moreau A; Burroni B; Djaileb L; Gressin R; Devillers A; Lamy T; Thieblemont C; Hermine O; Kraeber-Bodéré F; Le Gouill S; Bodet-Milin C
Haematologica; 2020 Jan; 105(1):e33-e36. PubMed ID: 31371411
[No Abstract] [Full Text] [Related]
39. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
[TBL] [Abstract][Full Text] [Related]
40. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
Schaefer NG; Strobel K; Taverna C; Hany TF
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
